Contract analysis

I. Executive Summary This memorandum analyzes the earnout provisions negotiated in the Asset Purchase Agreement (the "APA") between Genome Dx Therapeutics Inc. ("GDT" or "Seller") and Meridian Precision Diagnostics, Inc. ("Meridian" or "Buyer") for the sale of GDT's OncuPath™ companion diagnostics assay line (the "OncuPath™ Business" or the "Business"). The APA is expected to be executed tomorrow, May 10, 2023, with

II. Background and Strategic Context A. Transaction Overview Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered in San Diego, California. GDT is a portfolio company of Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle" or "PBP III"), a life sciences-focused private equity fund managed by Pinnacle Capital Management LLC, which holds approximately 68.4% of GDT's outstanding common

III. Earnout Milestone Definitions The Earnout Agreement, attached as Exhibit D to the APA, sets forth two discrete milestones, each with a defined trigger event, deadline, payment amount, and payment timing. The following sections analyze each milestone in detail. A. Milestone 1 — FDA Clearance/Approval of OncuPath-HER3™ ($8,000,000) Trigger Event. Milestone 1 is triggered upon FDA clearance (via the Section 510(k)

IV. Commercially Reasonable Efforts Standard A. Definition and Scope The Buyer's obligation to pursue achievement of the earnout milestones is governed by a "commercially reasonable efforts" standard, as set forth in Section 2.1 of the Earnout Agreement. The Buyer covenants to use commercially reasonable efforts to achieve each earnout milestone within the applicable deadline. The term "commercially reasonable effort

Section 2.3 of the Earnout Agreement includes a set of negative covenants designed to protect Seller against "sandbagging" — i.e., conduct by Buyer that is intended to prevent or delay the achievement of earnout milestones in order to avoid making the earnout payments. These provisions were a critical negotiating priority for Seller and reflect Delaware case law recognizing the implied covenant of good faith and fair

Section 2.4 of the Earnout Agreement establishes ongoing reporting and transparency obligations to ensure that Seller has adequate visibility into Buyer's development efforts during the Earnout Period. These obligations include: (a) Quarterly Written Reports. Buyer shall provide Seller with quarterly written reports on progress toward each earnout milestone, to be delivered within 30 days following the end of each ca

V. Dispute Resolution Mechanics The Earnout Agreement establishes a three-tier dispute resolution framework for resolving disputes relating to earnout milestone achievement, Buyer's compliance with the commercially reasonable efforts standard, and the calculation and payment of earnout amounts. The tiered structure is designed to encourage early, cost-effective resolution while preserving the parties' ability to obta

VI. Acceleration Provisions A. Buyer Change of Control

Section 3.1 of the Earnout Agreement provides that if Buyer undergoes a "Change of Control" at any time during the Earnout Period, all unpaid earnout milestone payments shall become immediately due and payable at their full stated amounts, without regard to whether the applicable milestone has been achieved or is reasonably likely to be achieved. "Change of Control" is defined in Section 1.3 of the Earnout Agreement

Section 3.2 of the Earnout Agreement provides a separate acceleration trigger in the event of Buyer's voluntary abandonment of the OncuPath-HER3™ development program. If Buyer voluntarily abandons the development of OncuPath-HER3™ — defined as any of the following actions taken without Seller's prior written consent and without demonstrating a bona fide scientific, regulatory, or safety basis: (a) Withdrawal of the P

VII. Anti-Embarrassment Protections A. Scope. Section 3.3 of the Earnout Agreement includes anti-embarrassment protections designed to ensure that Seller shares in any value appreciation attributable to the OncuPath-HER3™ program during the Earnout Period. Specifically, if Buyer divests, licenses, or otherwise transfers the OncuPath-HER3™ assay (or any successor assay based on the same underlying technology, as defin

VIII. Interplay with Other Transaction Terms A. Escrow Mechanics The APA provides for a $14,000,000 escrow deposit at Ashgrove Equity Partners Escrow Services, Inc. (Account No. 8841-7023-5500) to secure Seller's indemnification obligations under Article IX of the APA. The escrow is established at closing and will be maintained for the duration of the 18-month general survival period, subject to extensions for pendin

IX. Seller-Favorable Drafting Considerations and Risk Assessment A. Strengths of Current Earnout Structure Calderwood & Harkness has negotiated a number of Seller-favorable provisions that materially strengthen GDT's position with respect to the earnout. The principal strengths of the current structure are as follows: Objective, Verifiable Milestones. The earnout milestones are defined by reference to specific, objec

1. Monitoring and Engagement. Seller should actively monitor the quarterly reports provided by Buyer and exercise its in-person meeting rights to maintain direct visibility into the OncuPath-HER3™ development program. GDT should designate an internal point of contact (we recommend Dr. Vasquez's office or Rebecca Chiang, General Counsel) to receive and review each quarterly report, track progress against milestone tim

2. Prompt Dispute Resolution. If at any point Buyer's quarterly reports or other communications suggest that Buyer is deviating from the commercially reasonable efforts standard — for example, by reducing staffing, deprioritizing the OncuPath-HER3™ program, or failing to respond to FDA communications in a timely manner — Seller should promptly engage the dispute resolution mechanisms set forth in the Earnout Agreemen